China's volume-based procurement (VBP) scheme is already in its fourth round for medical devices – and 10th round for pharma – and companies affected by these price-cutting schemes should be preparing their growth strategies locally.
That was the advice of Hua Su, life science and healthcare practice leader and partner at Ernest & Young Parthenon, based in
The rationale behind the Chinese government’s price-cutting drive and implementation of VBP – also referred to in medtech circles as state-based procurement − is to lower prices based on international reference pricing and benchmark markets such as those of South Korea and Taiwan